ECSP034740A - Conjugados de pregabalina-lactosa - Google Patents

Conjugados de pregabalina-lactosa

Info

Publication number
ECSP034740A
ECSP034740A EC2003004740A ECSP034740A ECSP034740A EC SP034740 A ECSP034740 A EC SP034740A EC 2003004740 A EC2003004740 A EC 2003004740A EC SP034740 A ECSP034740 A EC SP034740A EC SP034740 A ECSP034740 A EC SP034740A
Authority
EC
Ecuador
Prior art keywords
disorders
diseases
pregabaline
present
subject
Prior art date
Application number
EC2003004740A
Other languages
English (en)
Inventor
Michael James Lovdahl
Timothy Hurley
Brian TOBIAS
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ECSP034740A publication Critical patent/ECSP034740A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

De acuerdo con la presente invención se proporcionan compuestos conjugados de prebalinalactosa. También se proporciona como parte de la presente invención un nuevo método para tratar en un sujeto trastornos o enfermedades del sistema nervioso central que incluyen trastornos de crisis-convulsivas, dolor, depresión, ansiedad, trastornos del sueño, trastornos consuntivos, psicosis, discinesia tardía, enfermedades de Huntington o Parkinson, administrando el sujeto una cantidad farmacéuticamente eficaz de un conjugado de pregabalina-lactosa
EC2003004740A 2001-03-30 2003-08-21 Conjugados de pregabalina-lactosa ECSP034740A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28017601P 2001-03-30 2001-03-30

Publications (1)

Publication Number Publication Date
ECSP034740A true ECSP034740A (es) 2003-12-24

Family

ID=23072002

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004740A ECSP034740A (es) 2001-03-30 2003-08-21 Conjugados de pregabalina-lactosa

Country Status (32)

Country Link
US (1) US7022678B2 (es)
EP (1) EP1377318A2 (es)
JP (1) JP2004524357A (es)
KR (1) KR20040008146A (es)
CN (1) CN1511043A (es)
AP (1) AP2003002873A0 (es)
AR (1) AR033024A1 (es)
BG (1) BG108193A (es)
BR (1) BR0208439A (es)
CA (1) CA2440468C (es)
CZ (1) CZ20032547A3 (es)
DO (1) DOP2002000356A (es)
EA (1) EA200300954A1 (es)
EC (1) ECSP034740A (es)
EE (1) EE200300480A (es)
GT (1) GT200200051A (es)
HU (1) HUP0303956A2 (es)
IL (1) IL157879A0 (es)
IS (1) IS6912A (es)
MA (1) MA27004A1 (es)
MX (1) MXPA03007437A (es)
NO (1) NO20034348D0 (es)
OA (1) OA12456A (es)
PA (1) PA8542101A1 (es)
PE (1) PE20021016A1 (es)
PL (1) PL369179A1 (es)
SK (1) SK11832003A3 (es)
SV (1) SV2003000928A (es)
TN (1) TNSN02038A1 (es)
UY (1) UY27233A1 (es)
WO (1) WO2002078747A2 (es)
ZA (1) ZA200306608B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
ES2398579T3 (es) * 2005-09-19 2013-03-20 Teva Pharmaceutical Industries Ltd Una síntesis asimétrica de ácido (S)-(+)-3-(aminometil)-5-metilhexanoico
DE102007019071A1 (de) 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
EP2297090A1 (en) * 2008-06-23 2011-03-23 Teva Pharmaceutical Industries Ltd. Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
WO2010115612A2 (en) 2009-04-10 2010-10-14 Synthon B.V. Pregabalin compositions
WO2010150221A1 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Taste masked pharmaceutical compositions of pregabalin
HU230031B1 (hu) * 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
CN103494796B (zh) * 2013-09-30 2016-01-20 浙江华义医药有限公司 普瑞巴林稳定的药物组合物及其制备方法
CN104370986B (zh) * 2014-10-28 2017-07-04 河南中烟工业有限责任公司 糖衍生物烟用增香保润剂Mal‑Pro、制备方法及其应用
CN104311608B (zh) * 2014-10-28 2016-10-05 河南中烟工业有限责任公司 亲水型烟草增香保润剂Mal-Hyp、制备方法及其应用
CN105520918B (zh) * 2015-12-31 2018-12-11 常州市阳光药业有限公司 普瑞巴林胶囊
CN105434395B (zh) * 2015-12-31 2018-12-11 常州市阳光药业有限公司 普瑞巴林胶囊及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
FR2781793B1 (fr) * 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
EP1121114B1 (en) * 1998-10-16 2007-01-10 Warner-Lambert Company Llc Use of gaba analogs for the manufacture of a medicament for the treatment of mania and bipolar disorders
CA2430298A1 (en) * 2000-11-30 2002-06-06 Banavara Lakshman Mylari Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Also Published As

Publication number Publication date
TNSN02038A1 (fr) 2005-12-23
WO2002078747A8 (en) 2003-12-04
CA2440468A1 (en) 2002-10-10
AP2003002873A0 (en) 2003-09-30
PE20021016A1 (es) 2002-11-14
CZ20032547A3 (en) 2004-04-14
US20020187941A1 (en) 2002-12-12
UY27233A1 (es) 2002-10-31
SK11832003A3 (sk) 2004-04-06
CN1511043A (zh) 2004-07-07
DOP2002000356A (es) 2002-12-15
HUP0303956A2 (hu) 2004-04-28
NO20034348L (no) 2003-09-29
EP1377318A2 (en) 2004-01-07
OA12456A (en) 2004-08-24
MXPA03007437A (es) 2003-11-18
WO2002078747A3 (en) 2003-10-09
MA27004A1 (fr) 2004-12-20
EA200300954A1 (ru) 2004-02-26
NO20034348D0 (no) 2003-09-29
US7022678B2 (en) 2006-04-04
BR0208439A (pt) 2004-03-23
PL369179A1 (en) 2005-04-18
AR033024A1 (es) 2003-12-03
SV2003000928A (es) 2003-07-29
BG108193A (en) 2004-09-30
IS6912A (is) 2003-08-14
IL157879A0 (en) 2004-03-28
ZA200306608B (en) 2004-11-25
KR20040008146A (ko) 2004-01-28
WO2002078747A9 (en) 2003-12-31
GT200200051A (es) 2002-11-15
JP2004524357A (ja) 2004-08-12
EE200300480A (et) 2003-12-15
WO2002078747A2 (en) 2002-10-10
CA2440468C (en) 2008-09-02
PA8542101A1 (es) 2002-10-28

Similar Documents

Publication Publication Date Title
ECSP034740A (es) Conjugados de pregabalina-lactosa
BR0316753A (pt) Método de tratamento para disfunção sexual
PA8597301A1 (es) Derivados de imidazol-4-il-etinil-piridina
BRPI0408026A (pt) Quinazolinas úteis como moduladores de canais de ìon
AR041725A1 (es) Prevencion, tratamiento de la enfermedad sinucleinopatica y composicion farmacologica
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
WO2002043652A3 (en) Anti-proliferative drugs
HN2001000037A (es) Derivados de eteres de pirazol como agentes antiinflamatorios/analgesicos
SV2003001107A (es) Imidazotriazinas ref.lea 35368
NO2012015I2 (no) Dapoxetine
CR6593A (es) Composicion constituida de material tramadol y una droga anticonvulsionante
WO2006020581A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
BR0213358A (pt) Uso de flibanserina
CR8095A (es) Anticuerpos humanizados que reconocen el cuerpo beta amiloideo
CR6735A (es) Substituted arylpyrazines
CO5370677A1 (es) Nuevos derivados heterociclicos de carbonil sustituido y su uso como ligantes receptores d3 de dopamina
EA200300266A1 (ru) Новые сложные эфиры апорфина и их применение в терапии
SI1819227T1 (sl) Farmacevtska formulacija decitabina
WO2007012061A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
BR0111892A (pt) Bis-arilsulfonas
UY27759A1 (es) Combinaciones de medicamentos que contienen compuestos heterocíclicos y un nuevo agente anticolinérgico.
EA200301023A1 (ru) Заместительная терапия эстрогенами
AU2003277280A1 (en) Biphenyls and fluorenes as imaging agents in alzheimer's disease
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
CR7060A (es) Conjugados de pregabalina-lactosa